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HPV Vaccines: Myths and Facts
Mehmet Faruk Kose and Emine Karabuk
Abstract
Many types of HPV virus found in nature are known to cause anogenital diseases 
and cancers in both of men and women. Genital condylomas caused by some types 
of HPV can cause important dermocosmetic, social, and psychological problems. 
On the other hand, cervical cancers caused by high-risk HPV types can be detected 
and treated in early stage or preinvasive period by using effective screening pro-
grams. But the main goal is to fight with the viruses causing the disease. Therefore, 
protective and preventive HPV virus vaccines are important. However, for effec-
tive administration of vaccines, it is necessary to know the effects of the vaccines, 
to whom it is applicable, any adverse effects, and to overcome prejudices against 
the vaccines and to clarify misinformation. In this chapter, in the light of current 
information about HPV vaccines, known facts and myths about vaccines are shared.
Keywords: HPV vaccines, cervical cancer, anogenital cancer, anogenital warts, 
efficacy, side effects
1. Introduction
The discovery of HPV (human papillomavirus) was awarded by Nobel Prize. 
Since 2008, when Prof. Dr. Harald zur Hausen (German Cancer Research Centre, 
Heidelberg, Germany) found the relationship between HPV and cervical cancer, 
the debate on HPV and its vaccine never ended (Figure 1).
Figure 1. 
HPV and cervical cancer (the Nobel Prize in Physiology or Medicine 2008).
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There are more than 200 known types of HPV and 35–40 types are responsi-
ble for anogenital diseases. Fifteen high-risk types were also related to cancer. In 
order of their level of connection to cancer, the HPV types are: 16, 18, 45, 31, 33, 
52, 58, 35, 59, 56, 51, 39, 68, 73, and 82. Out of those, 16 and 18 are responsible 
for 71–80% of the cancers and are five times more oncogenic than the other 13 
types. From the low-risk types, 6 and 11 are responsible for 90% of the anogeni-
tal wart [1].
Looking geographically, 16, 18, 45, 31, 33, 52, and 58 are the seven most preva-
lent types, with little variation between locations [1]. In Turkey, Usubütün et al. 
found that types 16 and 18 had 76% prevalence in cervical cancers. The first six 
types (16, 18, 45, 31, 33, and 52) are responsible for 90.6% of the cancers [2].
In Figure 2, the full structure of both early (E) and late (L) proteins of HPV are 
shown, as well as their functions.
In their lifetime, women have 80–85% chance to have an HPV infection, 
which means it is a widespread sexually transmitted disease. Speaking of sexually 
transmitted, 99% of all types are transmitted via sex, and using condoms do not 
protect from it (although some studies show that it protects up to 60%, theoreti-
cally any contact between testicals and the vulva is enough for transmission); 
it can spread even if a finger that had contact with the infected organ touches 
the opposite gender’s genetelia (less than 0.1% of all cases), and since the virus 
requires body heat; it cannot be transmitted via pools, toilets, baths, saunas, or 
any other non-living surface.
So is HPV a cervical cancer factor, and are there other HPV-related diseases? 
HPV-related diseases are: cervix, anus, vulva, penis, oropharynx, and oral cav-
ity cancers. The main reason for cervical cancer is HPV. In other words, cervical 
cancer cannot happen without HPV. HPV is also related to other diseases to some 
extent (Figure 3).
Figure 2. 
L and E proteins of HPV and their functions.
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Recently, its association with lung cancer has been shown. In a study by Xiong 
et al. in 17 countries with 6890 cases and 7474 control groups, squamous cell 
carcinoma, adenocarcinoma and small-cell carcinoma types showed an increase 
post-HPV infection (Total OR 3.64 (95% CI: 2.60–5.08) for HPV 16: 3.14 (95% CI: 
2.07–4.76) for HPV 18: 2.25 (95% CI: 1.49–3.40)) [4].
Apart from cancer, anogenital wart is one of the most important social prob-
lems. As seen in Figure 4 for England and the Wales, anogenital wart increases with 
a country’s level of development.
In Turkey, anogenital wart prevalence was found as 154/100,000 and in another 
study that was adjusted for age, point prevalence (lifetime incidence rate) was 3.8% 
for the full group, and 2.4% for the pregnant population. Prevalence study revealed 
similar results of recurrence with USA and Europe by 15–37% [5, 6].
The question, then, arises: Is HPV only for females? What about HPV in males? 
HPV has been shown to be associated with anogenital wart, anal and penile cancers 
in men [7, 8].
Figure 3. 
HPV-related cancers and their HPV prevalence [3].
Figure 4. 
Prevalence of anogenital wart in England and the Wales throughout the years (Health Protection Agency of 
England and Wales).
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Males are the carriers of this sexual-transmitted disease; however, the disease 
burden is mostly present in females.
So, is there any vaccine developed against this infectious disease, can this disease 
be eliminated?
First ever vaccination study was developed as a monovalent (for a single type) 
against 16 with a 100% protection rate [9]. This vaccine was not commercialized.
A bivalent (for 2-types) vaccine against the most cancer-linked types 16 and 18 
based on the previous study, as well as a quadrivalent (for four-types) vaccine based 
on recombinant virus-like particle (VLPs) were developed by the world-leader 
companies GSK and MSD [10, 11]. Then, a nonavalent (for nine-types) vaccine was 
developed and commercialized in order to protect against even more cancer-linked 
HPV types [12].
Since anogenital warts are one of the substantial social problems, it has not been 
available and bivalent vaccine against HPV 6 and 11 is still in progress. The current 
vaccines in use do not provide protection against HPV types associated with non-
wart anogenital warts and non-melanoma skin cancers (NMSC). Therefore, vaccina-
tion studies against L2 proteins are in progress in the phase of animal experiments.
The International Papillomavirus Society, in an excerpt in the Guardian, pointed 
to Australia as a model for eradicating cervical cancer; they discussed results in 
between 2005 and 2015 and showed vaccination rates at 78.6% for girls below the 
age of 15 and 72.9% for boys below the age of 15, since 2016 [13].
World Health Organization (WHO) has developed a strategy plan to eliminate 
cervical cancer. According to the strategy, to provide a total elimination from 
cervical cancer, up to 15 years of age 90% of the girls should be vaccinated, 70% of 
females aged between 35 and 45 should be screened via high sensitivity tests and 
90% of women should be successfully treated of cervical diseases (precancerous 
lesions and invasive cancers). World Health Organization stated that if these goals 
are reached by 2030, the elimination of cervical cancer would be possible in 2090 
(Figure 5) (https://www.who.int/docs/defaultsource/documents/cervical-cancer-
elimination-draft-strategy.pdf?sfvrsn=380979d6_4).
In Turkey, however, the situation is highly controversial. As of the last months 
of 2019, nonavalent is not licensed let alone being included in a vaccination pro-
gramme. Unfortunately, two of our worst examples for vaccination; polio and 
hepatitis B; shows a 17-year delay in adapting vaccination programs behind the rest 
of the world. In 1955, there were statements on Milliyet Journal’s columns such as 
Figure 5. 
Timeline for eliminating cervical cancer.
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“The discovery of Polio vaccine caused a stir in Turkey” and “The news of Polio 
caused an excitement in our country but Turkish practitioners do not want to make 
any statement before getting informed from authorities.” Seventeen years after 
these statements, polio was eliminated to be included in the vaccination programme 
of Turkey.
2. Myths
• Natural infection protects so there is no need for vaccination.
• Vaccinated children never experience HPV infection and never have HPV 
associated cancer throughout their lives.
• Vaccination cures their related disease.
• Antibody levels in blood are quite important; the protection loses its effect if 
the levels drop.
• Herd immunity (protection of the unvaccinated population) does not exist.
• Vaccinations are not effective when done at later ages.
• Smear or other HPV tests should be performed before the vaccination.
• If a pregnancy occurs during vaccination, it should be terminated.
• Vaccinated young girls have higher rates of sexually transmitted diseases since 
they feel more sexually comfortable.
• Autoimmune diseases such as primary ovarian deficiency and Guillain-Barre 
have higher rates among the vaccinated girls.
• There is cross-protection so vaccinations of HPV 16 and 18 are sufficient.
• If there is total protection against types in vaccinations, then cancer prevalence 
of other types will increase.
• Vaccines are not safe, there are deaths associated with the vaccine.
• Vaccines are not cost-effective, protected patients are not worth the cost.
3. Facts
3.1 Natural infection protects so there is no need for vaccination
HPV slithers through the cervical cracks and reaches basal cells in about 30 min-
utes and enters the cells to infect them. Since it does not stay in the vascular system, 
the antibody response does not form. Inside the cell, DNA is located episomally at 
first. Episomally located DNA causes a temporary infection and gets excreted with 
the cell when the cell is visible on the surface. If the DNA of the HPV gets integrated 
into the cell DNA, persistent infection will occur and some of them advance to 
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preinvasive lesions. Only 15 of 100 HPV-infected women will develop cervical 
intraepithelial neoplasia (CIN) while 60% of them will have regression and 25% of 
them continue as infection.
In a study by Viscidi et al. with the National Cancer Institute (NCI) on the 
“Guanacaste, Costa Rica NCI Program,” that included 10,049 women examined 
for over a 5-year period; natural HPV infection occurred on women independent 
of the type-based serological state. HPV infections from types 16, 18, and 31 rates 
were equal for both seronegative and seropositive cases. This is the clearest evidence 
which proves that natural infections do not protect against HPV [14].
3.2 Vaccinated children cannot get HPV or HPV-linked cancer in the future
Many patients as well as physicians have misinterpreted this issue. HPV-
vaccinated patients that develop HPV-related diseases are shown as exemplary 
cases. What is the right information, then? Considering the cervical cancer, only 15 
high-risk types can cause cancer. Types 16 and 18 that are included in the vaccines 
are responsible for 71–76% and the seven high-risk types in the nonavalent vac-
cines are responsible for 88–90% of all cervical cancer. Naturally, even nonavalent 
vaccines do not protect against all HPV types, and HPV infection can develop in the 
rest. Furthermore, we know that LSIL (low-grade squamous intraepithelial lesion) 
may develop not only through high-risk HPV types but also it can be caused by 
other types of HPV.
In the end, naïve (no prior contact with HPV) group children are protected close 
to 100% against the types included in the vaccine. Adults who have not developed the 
same type HPV before are also protected close to 100%. If they developed it before, 
they are instead protected against the other included types.
However, FUTURE III study shows us that the chance of developing both types 16 
and 18 infections is less than 1% [15]. In addition to this, Kang et al. studied the effi-
cacy of quadrivalent vaccines in 737 cases treated for CIN 3 over the course of 3 years. 
In this randomized controlled study, 360 vaccinated cases and 377 non-vaccinated 
cases were monitored in terms of recurrent diseases associated with certain HPV 
types. In the vaccinated group, recurrent infection rate was 2.5% while in the non-
vaccinated group, the rate was 8.5% (HR = 2.840; CI: 1.335–6.042; p < 0.01) [16].
As a summary, both vaccinated girls and boys can develop HPV infections, 
which can lead to cancer, with types that are not included in the vaccine. Anogenital 
warts can occur with HPV types other than 6 and 11, hence the quadrivalent and 
nonavalent vaccinated group can develop anogenital warts at a rate lower than 10%.
3.3 Vaccination cures their related disease
Vaccines do not treat HPV-associated diseases. They are not therapeutic. 
However, as stated in previous section, vaccines are effective in preventing recur-
rent infections.
3.4  Antibody levels in blood are quite important; the protection loses its effect if 
the levels drop
Both bivalent and quadrivalent HPV vaccines’ fundamental studies, FUTURE 
[15] and PATRICIA [17], recorded related blood antibody levels. In these studies, 
neutralizing antibody levels were measured for four different age groups: 15–25, 
26–35, 36–45, and 46–55 years old. For per protocol groups, both HPV 16 and 18 
neutralizing antibodies separately showed a peak at 7 months (after the third dose).
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Antibody levels were found to be at least 8 times higher compared to natural 
infections, even in the youngest age group. HPV vaccines were found to have a 
general characteristic to be effective when done in both childhood and later ages. 
Neutralizing antibody level of 4V HPV vaccine for type 18 started to fall starting at 
24 months and fell to the natural infection level at 55 months. Neutralizing antibod-
ies showed 76% decrease at 24 weeks and 56% at 36 weeks.
Does this decrease in antibody level correspond to a decrease in protection level 
against type 18? In a 2008 RCT study by Joura et al., the protection level against 
HPV type 18 was steady at 98.4% (95% CI: 90.5–100) even when the antibody levels 
fell [18]. Ault et al. also showed that at 4 years mark, CIN 2/3 protection levels were 
at 100% even when seropositivity dropped to 60% [19]. When we consider the 
HPV vaccinated population that did not follow the full protocol; or had one or two 
doses only, by the 15th year mark hepatitis B vaccine shows a similar result. One or 
two dose vaccination was shown to provide comparable protection to three-dose 
regimes [20]. Even though hepatitis B vaccinated population’s neutralizing antibody 
level was not measurable, the protection level was known to be still at 100%. This 
goal is presumed to be reflected on HPV vaccination soon. As in, changes in the 
neutralizing antibody levels do not affect the protection, which will stay at 100%.
3.5 Herd immunity does not exist
Herd immunity, or the increase in protection rate of the unvaccinated popula-
tion as the overall vaccination rate increases, is a well-known fact for all types of 
vaccines. In Sweden, even though quadrivalent HPV vaccination rates are very 
low, 15–44 years old unvaccinated men and women had significant decrease on the 
annual rate-of-change percentage [21]. Therefore, as the community vaccination 
rate increases, those who are not vaccinated with HPV-related vaccines will develop 
HPV-related diseases at a lower rate.
3.6 Vaccinations are not effective when done at later ages
It was shown that HPV vaccination generates high neutralizing antibody levels 
when done in early childhood as well as at later ages. PATRICIA and FUTURE studies, 
at four age groups of 15–25, 26–35, 36–45 and 46–55 years old, shows consistent anti-
body levels for all of them. Even if there is not a statistical significance on vaccination 
of the naïve population, it is expected to be more effective. However, for all three 
vaccinations, EMA (European Medicine Agency) does not provide a set age limit. 
After considering the available data and studies, EMA decided to lift the age limit on 
women. However, there is a soft 25 years-old upper limit for men. This age limit is due 
to follow-up case series not being available yet.
3.7 Smear or other HPV tests should be performed before the vaccination
Vaccination will not protect against infections that occurred prior to it. FUTURE 
III study shows us that developing both HPV 16 and 18 together has a chance less 
than 1%. According to abnormal smear results, HSIL and cancer are only correlated 
with high-risk HPV types. On the other hand, LSIL is correlated with both high-risk 
HPV types as well as others. Hence, HPV DNA test prior to vaccination can only tell 
for less than 1% of women if the vaccine cannot protect against the most prevalent 
types 16 and 18. Studies also show that vaccinations help reduce reinfection rate for 
prior type 16 and/or 18 infections. On top of the infections, a randomized control 
study on LEEP treated cases due to HSIL, shows us that vaccinated group had a 
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reduced reinfection rate at 2.5% compared to 8.5% [16]. According to this data, 
smear or HPV DNA tests are not required prior to vaccination.
3.8 If a pregnancy occurs during vaccination, it should be terminated
There are limited number of cases about uses of bivalent and quadrivalent HPV 
vaccination during pregnancy. Both vaccines are classified as category B due to prior 
data. Comparison between vaccinated and unvaccinated group did not show an 
increase in the infant’s congenital anomaly rates. However, due to unavailability of 
more data, vaccination during pregnancy is not recommended. This does not mean 
that the vaccination is done without knowledge of the pregnancy, that it should be 
aborted [22].
3.9  Due to decreased sexual fear, sexually transmitted disease rates increase 
among vaccinated girls
From a social, psychologic, and religious angle; parents of vaccinated girls 
wonder if the protection of the vaccine would urge them to be more sexually active 
at a younger age. It would be an issue if it was true. In order to answer this, a study 
published at Pediatrics reported sexually transmitted infections (STI) history of 
vaccinated girls. Mayhew et al. found that between the 42.5% cases without prior 
sexual relations and 57.5% cases with prior sexual relations, there was only a differ-
ence of OR 0:13 (95% CI: 0.03–0.69) which shows that vaccination did not change 
their sexual behavior [23].
3.10  Autoimmune diseases such as primary ovarian insufficiency and  
Guillain-Barre have higher rates among the vaccinated girls
In order to claim that a vaccination developed a disease, it needs to be within 
3 years. At the 9th-year mark of HPV vaccines, 170,000,000 doses of vaccines had 
been done. Out of this large sample size, only six cases in the literature show primer 
ovarian insufficiency. Looking closer, we see that three of these cases had irregular 
periods up to 15 years before vaccination. The other three cases had their diagnosis 
more than 3 years after vaccination [24].
In the placebo-controlled FUTURE III (quadrivalent HPV vaccine) study, in 
both the vaccinated and AAHS (regular saline, placebo) groups, autoimmune 
disease rates were at 2.3%. This is the clearest study that shows autoimmune disease 
rate does not increase in vaccinated population. In addition, in a large meta-analysis 
study by Genovese et al. (243,289 vaccinated and 248,820 control group) there was 
no correlation between HPV vaccines and autoimmune diseases [25].
3.11  Vaccines that include types 16 and 18 are enough for the rest due  
to cross-protection effect
The difference between cross-protection and cross-reaction is an important issue. 
Bivalent and quadrivalent HPV vaccines both show cross-reaction. Especially in biva-
lent HPV vaccines, researchers argued for cross-protection due to common ancestry 
of types 16 and 31 as well as 18 and 45. In bivalent vaccinated girls, HPV 31 and 45 
immune response, as well as GMTs and seropositivity rates were considered. Serum 
GMTs were 20 times higher than natural infections for HPV 31 and 45. This effect, 
however, is cross-reaction. Because the vaccinated girls and women lose the protection 
against HPV 31 and 45 by the end of 4th year in these bivalent HPV studies [26–28].
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In a report by the Centers for Disease Control and Prevention (CDC) in the USA, 
as of 2018, there are no bivalent or quadrivalent HPV vaccines in the market; only 
nonavalent HPV vaccine is sold [29].
3.12  If the vaccines include full protection against some types, cancer rates in 
the rest of the types will increase
This is a baseless theory from anti-vaccination group. Is it necessary to prove 
the opposite of this theory? Even so, there have been studies on the matter. In 1180 
vaccinated cases, anogenital non-vaccinated type HPV and genetic-related HPV 
16 and 18 types prevalence are studied. There was no change in the non-vaccinated 
HPV type prevalence [30].
3.13 Vaccines are not safe; there are deaths associated with the vaccine
Three independent institutes on the CDC Website are continuously monitor-
ing the safety of vaccines and the data is available for both experts and the com-
munity. Because in the USA, every drug that is on the market has an obligation for 
routine control. These vaccine-monitoring systems are: the Vaccine Adverse Event 
Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical 
Immunization Safety Assessment (CISA) Network; and any person who had an 
adverse effect from a vaccine can report to them freely.
Vaccines consist of VLPs (virus-like particles) made with recombinant technol-
ogy, that do not include any DNA but are identical to HPV in terms of structure. 
They cannot develop HPV infections or HPV-related cancer, as they do not include 
any DNA to reproduce. On the other hand, weakened or killed bacteria or virus 
vaccines do have a minute risk [31].
Side effects include redness in the vaccination site, minor pain, inflammation, 
and mild fever; like all childhood vaccinations. It could also cause nausea and diz-
ziness. Due to this, vaccinated people are recommended to rest for 15 minutes after. 
VAERS records show that when divided into critical side effects and non-critical 
side effects; side effect rates were on a steady decline since 2007. In theory, autoim-
mune diseases are the most common side effect claims. In a quadrivalent HPV 
vaccine in 1000 cases of 9–26 year-old girls and women, there were no differences 
in autoimmune diseases between the vaccine group and the adjuvant or physiologic 
serum group. Both groups reported a rate of 2.3%.
When nonavalent HPV vaccine was introduced after the quadrivalent vaccine, 
which had twice the amount of aluminum (500 μg = 0.5 mg) of the latter, several 
anti-vaccination physicians theorized that this would worsen the side effects. 
However, any side effect of the 0.5 mg AAHS in hepatitis B, which has been used for 
25 years, has never been proven. In a new study on the safety of aluminum in vac-
cines, the aluminum in the immunity-booster adjuvants had a high safety factor and 
did not cause any neurotoxicity [32]. Furthermore, we ingest more aluminum from 
drinking water (<0.2 ml/L), from many foods such as potatoes and spinach (<5 mg/
kg), from aluminum folio to preserve food, from food with aluminum supplements, 
and soy-based food (0.4–6 mg/L) compared to the vaccines (https://www.cfs.gov.
hk/…/files/RA35_Aluminium_in_Food_e.pdf).
Theory that quadrivalent and nonavalent HPV vaccines can cause primary 
ovarian insufficiency (POI) has been claimed by experts in many places including 
the social media. As described in detail in the previous section, there have been 
only 6 POI cases out of 170,000,000 doses of HPV vaccines in over 9 years. What 
is the incidence rate of POI in a normal population? Spontaneous POI for under 
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30-years old is about 0.1%, and for under 40-years old is about 1%. In Australia, 
out of 5,800,000 doses for 83% school-age girls, there was no relation between 
HPV and POI [33].
In Japan, there is a two-staged national vaccine program; quadrivalent HPV 
vaccine was implemented to the first stage in 2010 and was moved to the second 
stage in April 2013. This allowed only anyone that wanted to be vaccinated. The 
reason was abnormal uterus bleeding, excessive uterus bleeding, and headache. To 
address this, 71,117 women were studied and no relation between the symptoms 
and vaccination were found. As a result, vaccines were reimplemented into the first 
stage in June 2013 [34].
Considering mortality, CDC Website reports 117 deaths for the 80,000,000 
doses of vaccines from the related institutes and 51 of them had a known cause. 
These known causes were unrelated to vaccines. Recorded death causes included: 
traffic accident, homicide, epilepsy crisis for epilepsy diagnosed patients, pul-
monary embolism, drug overdose for drug abuse patients, acute myocarditis, 
and meningoencephalitis, influenza B, and diabetic ketoacidosis. There were five 
reported deaths after nonavalent vaccines were introduced: car accident, suicide, 
acute lymphoblastic leukemia, septic shock, and an unknown cause. There are 
many meta-analysis and reviews about vaccine safety readily available. There are 
no differences in between vaccinated and unvaccinated groups in terms of critical 
side effects.
3.14 Vaccines are not cost-effective; protected patients are not worth the cost
This is an interesting claim. Every single patient protected is worth the effort. 
Looking through a scientific perspective, many studies found that even the vaccines 
based on HPV 6/11 related warts, HPV 16/18 related precancerous lesions, and 
cervical cancer are cost effective [35–37].
4. Conclusion
HPV vaccines are recommended by WHO, CDC that are the world’s leading 
organizations, and related associations of all other developed countries, have not 
yet reached the deserved coverage rate. WHO described HPV vaccination as an 
essential part of its program when talking about the elimination of cervical cancer. 
The most well-known topic of all medical staff is “The worst vaccine is better than 
the best treatment.” As such, there are numbers of myths about HPV vaccines that 
we mentioned above. These issues should be well known to all of our community, 
especially health professionals, so that HPV vaccination can become widespread. 
We wanted to share the truths of these myths with you in the light of the evidences 
of today. In this article, neither of us have any conflict of interest.
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